UK markets close in 2 hours 43 minutes

Zymeworks Inc. (ZYME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.48-0.23 (-2.64%)
At close: 04:00PM EDT
8.48 0.00 (0.00%)
After hours: 05:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.71
Open8.54
Bid8.45 x 100
Ask8.51 x 200
Day's range8.42 - 8.55
52-week range6.01 - 13.14
Volume314,990
Avg. volume628,822
Market cap599.577M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-1.78
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.36
  • GlobeNewswire

    Zymeworks Announces Participation in Upcoming Investor Conferences

    VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on June 5-6 and a fireside chat

  • Simply Wall St.

    Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

    Zymeworks Inc. ( NASDAQ:ZYME ) just released its latest quarterly report and things are not looking great. It was not a...

  • GlobeNewswire

    Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

    Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in